tbuckley/cabot-search huggingface dataset:
Direct-to-Consumer Advertising of Prescription Drugs Can Inform the Public and Improve Health
Authors: Crystal Adams
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
CMV Infection and Disease after Nonmyeloablative (NM) HCT Revisited: Incidence, Risk Factors, Ganciclovir-Related Neutropenia and Outcome.
Authors: L. Norasetthada, K. Kirby, B. Sandmaier, D. Maloney, M. Maris, C. Davis, L. Corey, R. Storb, M. Boeckh
Journal: Blood (2005)
Detection of Loss of A20 Gene by FICTION in Hodgkin's Lymphoma Cases.
Authors: Junko Nomoto, Nobuhiro Hiramoto, Motohiro Kato, Masashi Sanada, Akiko Maeshima, Fumie Hosoda, Yoshitaka Asakura, Dai Maruyama, Takashi Watanabe, Kensei Tobinai, Hitoshi Nakagama, Seishi Ogawa, Yukio Kobayashi
Journal: Blood (2009)
Treatment frequency and mortality among incident hemodialysis patients in the United States comparing incremental with standard and more frequent dialysis
Authors: Anna Mathew, Yoshitsugu Obi, Connie M. Rhee, Joline L.T. Chen, Gaurang Shah, Wei-Ling Lau, Csaba P. Kovesdy, Rajnish Mehrotra, Kamyar Kalantar-Zadeh
Journal: Kidney International (2016)
Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
Authors: Zuzana Motovska, Ota Hlinomaz, Roman Miklik, Milan Hromadka, Ivo Varvarovsky, Jaroslav Dusek, Jiri Knot, Jiri Jarkovsky, Petr Kala, Richard Rokyta, Frantisek Tousek, Petra Kramarikova, Bohumil Majtan, Stanislav Simek, Marian Branny, Jan Mrozek, Pavel Cervinka, Jiri Ostransky, Petr Widimsky
Journal: Circulation (2016)

Background: No randomized head-to-head comparison of the efficacy and safety of ticagrelor and prasugrel has been published in the 7 years since the higher efficacy of these newer P2Y 12 inhibitors were first demonstrated relative to clopidogrel. Methods: This academic study was designed to compare the efficacy and safety of prasugrel and ticagrelor in acute myocardial infarction treated with primary or immediate percutaneous coronary intervention. A total of 1230 patients were randomly assigned across 14 sites to either prasugrel or ticagrelor, which was initiated before percutaneous coronary intervention. Nearly 4% were in cardiogenic shock, and 5.2% were on mechanical ventilation. The primary end point was defined as death, reinfarction, urgent target vessel revascularization, stroke, or serious bleeding requiring transfusion or prolonging hospitalization at 7 days (to reflect primarily the in-hospital phase). This analysis presents data from the first 30 days (key secondary end point). The total follow-up will be 1 year for all patients and will be completed in 2017. Results: The study was prematurely terminated for futility. The occurrence of the primary end point did not differ between groups receiving prasugrel and ticagrelor (4.0% and 4.1%, respectively; odds ratio, 0.98; 95% confidence interval, 0.55–1.73; P =0.939). No significant difference was found in any of the components of the primary end point. The occurrence of key secondary end point within 30 days, composed of cardiovascular death, nonfatal myocardial infarction, or stroke, did not show any significant difference between prasugrel and ticagrelor (2.7% and 2.5%, respectively; odds ratio, 1.06; 95% confidence interval, 0.53–2.15; P =0.864). Conclusions: This head-to-head comparison of prasugrel and ticagrelor does not support the hypothesis that one is more effective or safer than the other in preventing ischemic and bleeding events in the acute phase of myocardial infarction treated with a primary percutaneous coronary intervention strategy. The observed rates of major outcomes were similar but with broad confidence intervals around the estimates. These interesting observations need to be confirmed in a larger trial. Clinical Trial Registration: URL: http://www.ClinicalTrials.gov . Unique identifier: NCT02808767.
How Best to Approach Surgery for Primary Hyperparathyroidism—Can We All Agree?
Authors: Julie Ann Sosa
Journal: JAMA Surgery (2016)

Scott M. Wilhelm, MD; Tracy S. Wang, MD, MPH; Daniel T. Ruan, MD; James A. Lee, MD; Sylvia L. Asa, MD, PhD; Quan-Yang Duh, MD; Gerard M. Doherty, MD; Miguel F. Herrera, MD, PhD; Janice L. Pasieka, MD; Nancy D. Perrier, MD; Shonni J. Silverberg, MD; Carmen C. Solórzano, MD; Cord Sturgeon, MD; Mitchell E. Tublin, MD; Robert Udelsman, MD, MBA; Sally E. Carty, MD
Expanding the Health Care Response to Mass Violence
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Donor faecal transplantation is highly curative in recurrent<i>C difficile</i>infection, trial finds
Authors: Susan Mayor
Journal: BMJ (2016)

Faecal transplantation with donor stool is more effective than transplanting a patient’s own stool in preventing further Clostridium difficile episodes in people with recurrent infection, results from a randomised trial of faecal transplantation have shown.1

C difficile infection is one of the most common healthcare associated infections. Antibiotic treatment for the condition is often ineffective, and recurrent infections are common, requiring prolonged courses of antibiotics. Faecal transplantation …
Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer
Authors: H. Imaoka, Y. Toiyama, H. Fujikawa, J. Hiro, S. Saigusa, K. Tanaka, Y. Inoue, Y. Mohri, T. Mori, T. Kato, S. Toden, A. Goel, M. Kusunoki
Journal: Annals of Oncology (2016)
Practice standardization in the staging and treatment of colon cancer at Intermountain Healthcare.
Authors: J. R. Whisenant, T. Belnap, B. D. Rowley, K. Alleman, K. G. Rowe, C. Jones, W. T. Sause
Journal: Journal of Clinical Oncology (2010)

6053 Background: Intermountain Healthcare is a network of 24 urban and rural hospitals including 9 comprehensive cancer centers serving Utah and southeastern Idaho. This project builds on the institution's long history of quality improvement and was undertaken to standardize the treatment of colon cancer with respect to surgery, pathology and medical oncology. Methods: A multidisciplinary physician-based development team identified the treatment of colon cancer as an area of interest, collected baseline data to assess current practice, and developed system wide goals to ensure optimal staging and treatment for patients. Following a review of existing literature and an evaluation of national guidelines, the team set a goal to remove and evaluate at least 12 lymph nodes in 90% of stage I-III colon cancer patients who undergo resection with curative intent. The next year the development team added a goal to ensure that 80% of stage III colon cancer patients receive chemotherapy. Both goals were developed and implemented using a similar process of ongoing data collection, analysis and feedback, physician education, regular review of noncompliant charts and constant monitoring by the development team. Both goals are still monitored on an ongoing basis. Results: Lymph node removal data were collected on all stage I-III colon cancer patients undergoing potentially curative colon cancer resection after January 1, 2007. Following standardization, the percentage of cases in which a minimum of 12 lymph nodes were evaluated increased from 78.8% (n = 99) to 95.1% (n = 102) (p = 0.001). Likewise, the percent of stage III colon cancer patients undergoing surgery beginning January 1, 2008 who received chemotherapy increased from 68.2% (n = 44) to 86.5% (n = 37) (p = 0.068). Following standardization, all 37 stage III patients were seen by a medical oncologist in consultation and offered chemotherapy. Conclusions: Practice standardization is crucial to ensuring the adoption and adherence to best practice guidelines and can be achieved in multiple hospitals and among multiple physician specialties. This requires validated organizational processes, physician leadership, ongoing data collection and constant monitoring. No significant financial relationships to disclose.
Clinicopathological Features and Outcome of Der(1;7)(q10;p10) In Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Single-Center Analysis of Japanese Patients
Authors: Hiroki Yokoyama, Noriko Usui, Nobuaki Dobashi, Shingo Yano, Yuichi Yahagi, Yutaka Takei, Katsuki Sugiyama, Yoji Ogasawara, Shinobu Takahara, Yuko Yamaguchi, Takeshi Saito, Takaki Shimada, Fumi Mizorogi, Ken Kaito, Keisuke Aiba
Journal: Blood (2010)
A reference panel of 64,976 haplotypes for genotype imputation
Authors: Shane McCarthy, Sayantan Das, Warren Kretzschmar, Olivier Delaneau, Andrew R Wood, Alexander Teumer, Hyun Min Kang, Christian Fuchsberger, Petr Danecek, Kevin Sharp, Yang Luo, Carlo Sidore, Alan Kwong, Nicholas Timpson, Seppo Koskinen, Scott Vrieze, Laura J Scott, He Zhang, Anubha Mahajan, Jan Veldink, Ulrike Peters, Carlos Pato, Cornelia M van Duijn, Christopher E Gillies, Ilaria Gandin, Massimo Mezzavilla, Arthur Gilly, Massimiliano Cocca, Michela Traglia, Andrea Angius, Jeffrey C Barrett, Dorrett Boomsma, Kari Branham, Gerome Breen, Chad M Brummett, Fabio Busonero, Harry Campbell, Andrew Chan, Sai Chen, Emily Chew, Francis S Collins, Laura J Corbin, George Davey Smith, George Dedoussis, Marcus Dorr, Aliki-Eleni Farmaki, Luigi Ferrucci, Lukas Forer, Ross M Fraser, Stacey Gabriel, Shawn Levy, Leif Groop, Tabitha Harrison, Andrew Hattersley, Oddgeir L Holmen, Kristian Hveem, Matthias Kretzler, James C Lee, Matt McGue, Thomas Meitinger, David Melzer, Josine L Min, Karen L Mohlke, John B Vincent, Matthias Nauck, Deborah Nickerson, Aarno Palotie, Michele Pato, Nicola Pirastu, Melvin McInnis, J Brent Richards, Cinzia Sala, Veikko Salomaa, David Schlessinger, Sebastian Schoenherr, P Eline Slagboom, Kerrin Small, Timothy Spector, Dwight Stambolian, Marcus Tuke, Jaakko Tuomilehto, Leonard H Van den Berg, Wouter Van Rheenen, Uwe Volker, Cisca Wijmenga, Daniela Toniolo, Eleftheria Zeggini, Paolo Gasparini, Matthew G Sampson, James F Wilson, Timothy Frayling, Paul I W de Bakker, Morris A Swertz, Steven McCarroll, Charles Kooperberg, Annelot Dekker, David Altshuler, Cristen Willer, William Iacono, Samuli Ripatti, Nicole Soranzo, Klaudia Walter, Anand Swaroop, Francesco Cucca, Carl A Anderson, Richard M Myers, Michael Boehnke, Mark I McCarthy, Richard Durbin
Journal: Nature Genetics (2016)
Assay Detects Drug-Resistance Genes
Authors: Rebecca Voelker
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Elevation of Fetal Hemoglobin (HbF) by Novel Alkylating Agents in Human Erythroid Cells; Synergistic Effects with Established HbF-Inducing Agents.
Authors: I. Chiotoglou, M. Samara, S. Likousi, S. Samara, Z. Iakovidou, E. Mioglou, D. Mourelatos, M. Papadakis, P. Liakos, Panagoula Kollia
Journal: Blood (2006)
Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364).
Authors: Richard F Schlenk, Andreas Reiter, Norbert Gattermann, Holger Hebart, Edgar Jost, Uwe Platzbecker, Andreas Hochhaus, Cornelius F. Waller, Philippe Schafhausen, Igor W. Blau, Walter Verbeek, Martin Werner, Hans H. Kreipe, Carolin Mahler, Silja Mack, Stefanie Schauer, Sabine Ostlender, Frank Stegelmann, Axel Benner, Martin Griesshammer, Konstanze Döhner
Journal: Blood (2012)
Quality of Care
Authors: Madhu J. John
Journal: JAMA (1992)

<h3>To the Editor.</h3> —Chassin's Editorial<sup>1</sup>regarding the underuse of the breast-conserving surgery (BCS) option for early breast cancer suggests that oncologists who treat this cancer should not be concerned with the fact that the vast majority of American women do not opt for the recommended preservation procedure as suggested by Lazovich et al<sup>2</sup>in the same issue. Progress in the management of oncologic conditions is measured not only in improving cure rates but also by finding treatment techniques that preserve anatomy and function without jeopardizing the cure rates achieved by treatment methods in which the primary tumor site is removed or sacrificed. In fact, surgical oncologists have welcomed preservation procedures in the treatment of cancers of the head and neck region, esophagus, bladder, and extremities. Chassin suggests that physicians may be failing to communicate the BCS option adequately. I believe that more women would opt for BCS if
Site‐Specific In Vivo Bioorthogonal Ligation via Chemical Modulation
Authors: Heebeom Koo, Jeong Heon Lee, Kai Bao, Yunshan Wu, Georges El Fakhri, Maged Henary, Seok Hyun Yun, Hak Soo Choi
Journal: Advanced Healthcare Materials (2016)

A critical limitation of bioorthogonal click chemistry for in vivo applications has been its low reaction efficiency due to the pharmacokinetic barriers, such as blood distribution, circulation, and elimination in living organisms. To identify key factors that dominate the efficiency of click chemistry, here a rational design of near‐infrared fluorophores containing tetrazine as a click moiety is proposed. Using trans ‐cyclooctene‐modified cells in live mice, it is found that the in vivo click chemistry can be improved by subtle changes in lipophilicity and surface charges of intravenously administered moieties. By controlling pharmacokinetics, biodistribution, and clearance of click moieties, it is proved that the chemical structure dominates the fate of in vivo click ligation.
Cognitive dysfunction in relation to endothelial function, structural changes of large vessels and left ventricular function in patients with chronic heart failure
Authors: A.A. Shchendrygina, Y.N. Belenkov, E.Y. Privalova, N.A. Pavlov, E.A. Zheleznykh, Y.A. Danilogorskaya
Journal: European Journal of Heart Failure (2013)
Authors’ reply: Prevention of congenital rubella and congenital varicella in Europe
Authors: E Pandolfi
Journal: Eurosurveillance (2009)

Preview this article: Authors’ reply: Prevention of congenital rubella and congenital varicella in Europe, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/14/14/art19168-en-1.gif
Front - Line Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves the Time to Treatment Failure and Overall Survival in Elderly Patients with Advanced Stage Follicular Lymphoma - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).
Authors: Christian Buske, Michael Kneba, Eva Lengfelder, Michael Pfreundschuh, Wolf-Dieter Ludwig, Ullrich Graeven, Michael Hallek, Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann
Journal: Blood (2006)
In Vitro Preactivation of PBMCs with PM-mb21-41BBL Particles Stimulates in Vivo Expansion of NK Cells Under Low IL-2 in NSG Mice
Authors: Jeremiah L Oyer, Veethika Pandey, Robert Y Igarashi, Dominic A Colosimo, Melhem M. Solh, Deborah A Altomare, Alicja J Copik
Journal: Blood (2014)
VARPRISM: incorporating variant prioritization in tests of de novo mutation association
Authors: Hao Hu, Hilary Coon, Man Li, Mark Yandell, Chad D. Huff
Journal: Genome Medicine (2016)

Patients with certain genetic diseases, such as autism spectrum disorder, have increased rates of de novo mutations within some protein-coding genes. We introduce the VARiant PRIoritization SuM (VARPRISM), a software package which incorporates functional variant prioritization information to improve the power to detect de novo mutations influencing disease risk. VARPRISM evaluates the consequence of any given exonic mutation on the protein sequence to estimate the likelihood that the mutation is benign or damaging and conducts a likelihood ratio test on the gene level. We analyzed the Simons Simplex Collection of 2508 parent-offspring autism trios using VARPRISM, replicating 44 genes previously implicated in autism susceptibility and identifying 20 additional candidate genes, including MYO1E, KCND3, PDCD1, DLX3, and TSPAN4 (false discovery rate < 0.3). By incorporating functional predictions, VARPRISM improved the statistical power to identify de novo mutations increasing disease risks. VARPRISM is available at http://www.hufflab.org/software/VARPRISM .
Insulin Therapy and Lipid Overload in Type 2 Diabetes
Authors: Raffaele Marfella
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
KEYNOTE-181: Phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma.
Authors: Toshihiko Doi, Jaafar Bennouna, Lin Shen, Peter C. Enzinger, Ruixue Wang, Ildiko Csiki, Minori Koshiji, Manish A. Shah
Journal: Journal of Clinical Oncology (2016)

TPS4140 Background: Tumors can hijack the PD-1 pathway to suppress immune control. Overexpression of the PD-1 ligand PD-L1 in esophageal cancer may be associated with a poor prognosis. Pembrolizumab (pembro) is a monoclonal antibody that can reinstate the antitumor autoimmune response by blocking the PD-1–ligand interaction. It demonstrated antitumor activity (ORR, 30.4%; DOR, 40 weeks) and was well tolerated in patients with PD-L1+advanced esophageal cancer (phase 1b KEYNOTE-028). The open-label, randomized, phase 3 KEYNOTE-181 trial (NCT02564263) will compare the tumor response to pembro relative to single-agent chemotherapy in previously treated advanced/metastatic (a/m) esophageal cancer. Methods: Key eligibility criteria include age ≥ 18 years, a/m adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ), measurable disease, documented PD during/after first-line therapy, ECOG PS 0-1, no active autoimmune disease or CNS metastases, and provision of a tissue sample for biomarker analysis. HER2 status must be determined for patients with EGJ adenocarcinoma; if HER2+, there must be documentation of PD on trastuzumab-containing therapy. Eligible patients are to be randomized (unblinded) 1:1 to IV pembro 200 mg Q3W or investigator's choice of paclitaxel 80-100 mg/m2 on days 1, 8, and 15 Q4W, docetaxel 75 mg/m2 Q3W, or irinotecan 180 mg/m2 Q2W. Treatment is to continue until documented PD, intolerable toxicity, patient/investigator decision, or (for pembro) until 35 cycles (~2 years). AEs are to be monitored throughout treatment and for 30 days thereafter (90 days for serious AEs). Tumor response will be assessed Q9W per RECIST v1.1 and adapted immune-related RECIST (irRECIST; central imaging vendor review). All patients will be followed Q9W for OS until death, withdrawal of consent, or end of study. Primary efficacy end points are PFS (per RECIST v1.1, blinded central imaging vendor review) and OS. Secondary end points include ORR (per RECIST v1.1, blinded central imaging vendor review). Approximately 600 patients will be enrolled. Clinical trial information: NCT02564263.